Synergistic increase in nerve growth factor secretion by cultured vascular smooth muscle cells treated with injury-related growth factors

Douglas J. Creedon, Jeremy B. Tuttle

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Vascular smooth muscle (VSM) cells comprise one of the primary targets of the sympathetic nervous system and have been shown to secrete nerve growth factor (NGF). There is increasing evidence that changes in the levels of NGF in the adult may underlie certain pathological conditions. To investigate the potential role of altered NGF production in vascular disease, VSM cell cultures were treated with injury-related growth factors and the culture medium was assayed for NGF using a two-site enzyme-linked immunosorbent assay (ELISA). Platelet-derived growth factor (PDGF), a potent VSM mitogen, caused a dose-dependent increase in NGF secretion. After 4 hr, PDGF-treated cultures contained 10 times more NGF than control cultures. NGF release remained elevated for 48 hr, but the peak secretion occurred in the first 12 hr after treatment. Transforming growth factor beta (TGF-β) caused a fivefold increase in NGF at 4 hr when added alone, but synergized with PDGF yielding approximately 50 times more NGF than control cultures. TGF-β and epidermal growth factor (EGF) also displayed synergism. In contrast, basic fibroblast growth factor (bFGF), which had a modest effect alone, appeared to be additive with TGF-β. Similarly, interleukin 1-beta (IL-1β), which mediates increased NGF synthesis in sciatic nerve lesions (Lindholm et al.: Nature 330:658-659, 1987), showed no synergism with TGF-β.

Original languageEnglish (US)
Pages (from-to)277-286
Number of pages10
JournalJournal of Neuroscience Research
Volume47
Issue number3
DOIs
StatePublished - Feb 1 1997
Externally publishedYes

Fingerprint

Nerve Growth Factor
Vascular Smooth Muscle
Smooth Muscle Myocytes
Intercellular Signaling Peptides and Proteins
Wounds and Injuries
Transforming Growth Factor beta
Platelet-Derived Growth Factor
Sciatic Neuropathy
Sympathetic Nervous System
Fibroblast Growth Factor 2
Interleukin-1beta
Vascular Diseases
Mitogens
Epidermal Growth Factor
Culture Media
Cell Culture Techniques
Enzyme-Linked Immunosorbent Assay

Keywords

  • atherosclerosis
  • EGF
  • FGF
  • hypertension
  • IL-1β
  • NGF ELISA
  • PDGF
  • TGF-β
  • vascular disease

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Synergistic increase in nerve growth factor secretion by cultured vascular smooth muscle cells treated with injury-related growth factors. / Creedon, Douglas J.; Tuttle, Jeremy B.

In: Journal of Neuroscience Research, Vol. 47, No. 3, 01.02.1997, p. 277-286.

Research output: Contribution to journalArticle

@article{065e53231b994144b4c819c62c947e2d,
title = "Synergistic increase in nerve growth factor secretion by cultured vascular smooth muscle cells treated with injury-related growth factors",
abstract = "Vascular smooth muscle (VSM) cells comprise one of the primary targets of the sympathetic nervous system and have been shown to secrete nerve growth factor (NGF). There is increasing evidence that changes in the levels of NGF in the adult may underlie certain pathological conditions. To investigate the potential role of altered NGF production in vascular disease, VSM cell cultures were treated with injury-related growth factors and the culture medium was assayed for NGF using a two-site enzyme-linked immunosorbent assay (ELISA). Platelet-derived growth factor (PDGF), a potent VSM mitogen, caused a dose-dependent increase in NGF secretion. After 4 hr, PDGF-treated cultures contained 10 times more NGF than control cultures. NGF release remained elevated for 48 hr, but the peak secretion occurred in the first 12 hr after treatment. Transforming growth factor beta (TGF-β) caused a fivefold increase in NGF at 4 hr when added alone, but synergized with PDGF yielding approximately 50 times more NGF than control cultures. TGF-β and epidermal growth factor (EGF) also displayed synergism. In contrast, basic fibroblast growth factor (bFGF), which had a modest effect alone, appeared to be additive with TGF-β. Similarly, interleukin 1-beta (IL-1β), which mediates increased NGF synthesis in sciatic nerve lesions (Lindholm et al.: Nature 330:658-659, 1987), showed no synergism with TGF-β.",
keywords = "atherosclerosis, EGF, FGF, hypertension, IL-1β, NGF ELISA, PDGF, TGF-β, vascular disease",
author = "Creedon, {Douglas J.} and Tuttle, {Jeremy B.}",
year = "1997",
month = "2",
day = "1",
doi = "10.1002/(SICI)1097-4547(19970201)47:3<277::AID-JNR6>3.0.CO;2-F",
language = "English (US)",
volume = "47",
pages = "277--286",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Synergistic increase in nerve growth factor secretion by cultured vascular smooth muscle cells treated with injury-related growth factors

AU - Creedon, Douglas J.

AU - Tuttle, Jeremy B.

PY - 1997/2/1

Y1 - 1997/2/1

N2 - Vascular smooth muscle (VSM) cells comprise one of the primary targets of the sympathetic nervous system and have been shown to secrete nerve growth factor (NGF). There is increasing evidence that changes in the levels of NGF in the adult may underlie certain pathological conditions. To investigate the potential role of altered NGF production in vascular disease, VSM cell cultures were treated with injury-related growth factors and the culture medium was assayed for NGF using a two-site enzyme-linked immunosorbent assay (ELISA). Platelet-derived growth factor (PDGF), a potent VSM mitogen, caused a dose-dependent increase in NGF secretion. After 4 hr, PDGF-treated cultures contained 10 times more NGF than control cultures. NGF release remained elevated for 48 hr, but the peak secretion occurred in the first 12 hr after treatment. Transforming growth factor beta (TGF-β) caused a fivefold increase in NGF at 4 hr when added alone, but synergized with PDGF yielding approximately 50 times more NGF than control cultures. TGF-β and epidermal growth factor (EGF) also displayed synergism. In contrast, basic fibroblast growth factor (bFGF), which had a modest effect alone, appeared to be additive with TGF-β. Similarly, interleukin 1-beta (IL-1β), which mediates increased NGF synthesis in sciatic nerve lesions (Lindholm et al.: Nature 330:658-659, 1987), showed no synergism with TGF-β.

AB - Vascular smooth muscle (VSM) cells comprise one of the primary targets of the sympathetic nervous system and have been shown to secrete nerve growth factor (NGF). There is increasing evidence that changes in the levels of NGF in the adult may underlie certain pathological conditions. To investigate the potential role of altered NGF production in vascular disease, VSM cell cultures were treated with injury-related growth factors and the culture medium was assayed for NGF using a two-site enzyme-linked immunosorbent assay (ELISA). Platelet-derived growth factor (PDGF), a potent VSM mitogen, caused a dose-dependent increase in NGF secretion. After 4 hr, PDGF-treated cultures contained 10 times more NGF than control cultures. NGF release remained elevated for 48 hr, but the peak secretion occurred in the first 12 hr after treatment. Transforming growth factor beta (TGF-β) caused a fivefold increase in NGF at 4 hr when added alone, but synergized with PDGF yielding approximately 50 times more NGF than control cultures. TGF-β and epidermal growth factor (EGF) also displayed synergism. In contrast, basic fibroblast growth factor (bFGF), which had a modest effect alone, appeared to be additive with TGF-β. Similarly, interleukin 1-beta (IL-1β), which mediates increased NGF synthesis in sciatic nerve lesions (Lindholm et al.: Nature 330:658-659, 1987), showed no synergism with TGF-β.

KW - atherosclerosis

KW - EGF

KW - FGF

KW - hypertension

KW - IL-1β

KW - NGF ELISA

KW - PDGF

KW - TGF-β

KW - vascular disease

UR - http://www.scopus.com/inward/record.url?scp=0031013273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031013273&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-4547(19970201)47:3<277::AID-JNR6>3.0.CO;2-F

DO - 10.1002/(SICI)1097-4547(19970201)47:3<277::AID-JNR6>3.0.CO;2-F

M3 - Article

C2 - 9039650

AN - SCOPUS:0031013273

VL - 47

SP - 277

EP - 286

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 3

ER -